EGFR and neoplasm: To further interrogate the role of T cell-dependent immune response, female BALB/c mice bearing TUBO-EGFR tumors were treated with CTX + IL-1α-NP (Fig. 6A,B) as already described in Fig. 5 with or without anti-CD4 (100 μg (clone GK1.5)) (Fig. 6A,C) or anti-CD8 (300 μg (clone 53–6.7)) (Fig. 6A,D) 1 and 3 days prior to tumor inoculation, and every 3–4 days after tumor inoculation.